“So looking ahead, we are encouraged by the momentum building across our portfolio and expect growth to accelerate as end markets continue to improve.”

In context

“l continue to execute well globally. For the full year 2026, we anticipate core revenue growth in the 3% to 6% range. Additionally, we are initiating full-year adjusted diluted EPS guidance in the range of $8.35 to $8.50. In the first quarter, we expect core revenue to be up low single digits. Additionally, we expect the first-quarter adjusted operating profit margin of approximately 28.5%. So to wrap up, we are pleased with our solid finish to the year and proud of the work our teams did in 2025 to reliably support our customers through a dynamic macro environment. They did a tremendous job staying focused on what we can control, running the Danaher business system playbook to offset cost pressures and deliver productivity gains while continuing to invest in innovation for the long term. So looking ahead, we are encouraged by the momentum building across our portfolio and expect growth to accelerate as end markets continue to improve. Our strong positioning in attractive end markets and high recurring revenue business models support our long-term expectation for high single-digit core growth with a differentiated margin and cash flow profile. So with the powerful combination of our differentiated portfolio, talented team, and strong balance sheet, all powered by the Danaher Business System, we feel well-positioned to create long-term shareholder value while making a meaningful positive impact on human health. So with that, I will turn the call back over to John. John Bedford: Thank you, Rainer. That concludes our formal comments. We are now ready for questions. Operator: Thank you. If you would like to ask a question, please press star 1 on your keypad. To leave the queue at any time, press star 2. Once again, that is”